title: Adherence improvement in Dutch glaucoma patients: a randomized controlled trial.
abstract: OBJECTIVE
  To study the effect of patient education and the TravAlert(®) -Eyot(®) drop guider on intraocular pressure (IOP) and adherence in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) monitored with the TravAlert(®) dosing aid.
  
  
  METHODS
  Multicentre, randomized, controlled clinical trial among 18 Dutch hospitals. Patients were randomized to one of the four study arms: (1) use of the dosing aid, (2) use of the dosing aid with the drop guider, (3) use of the dosing aid together with patient education or (4) use of the dosing aid and drop guider together with patient education. IOP was recorded at baseline and after 3 and 6 months. Data on adherence generated by the dosing aid were collected and studied at the end of the study.
  
  
  RESULTS
  Mean IOP dropped from 20.3 ± 5.7 mmHg at baseline to 16.3 ± 4.0 mmHg (right eye) after 6 months and from 20.2 ± 5.9 mmHg to 16.4 ± 4.1 mmHg (left eye). The mean adherence rate was 0.91 ± 0.1. IOP and adherence rate were not statistically different between the study arms. Patients with 'drug holidays' had a significantly higher mean IOP after 6 months. Patients who used the drop guider were less adherent. A lower adherence level was also associated with new patients with glaucoma and patients with a lower level of knowledge on glaucoma.
  
  
  CONCLUSIONS
  Patient education is especially useful for new patients with glaucoma. The use of a drop guider does not improve adherence. Especially patients with 'drug holidays' are at risk for developing uncontrolled IOP levels.
authors.affiliation: University Eye Clinic, Maastricht University Medical Centre, Maastricht, The NetherlandsDepartment of Ophthalmology, Catharina Hospital, Eindhoven, The NetherlandsDepartment of Ophthalmology, Jeroen Bosch Hospital, 's Hertogenbosch, The NetherlandsDepartment of Ophthalmology, Amphia Hospital Langendijk, Breda, The Netherlands.
authors.forename: Henny J M
authors.initials: HJ
authors.lastname: Beckers
authors.forename: Carroll A B
authors.initials: CA
authors.lastname: Webers
authors.forename: Michiel J W M
authors.initials: MJ
authors.lastname: Busch
authors.forename: Hendrik M A
authors.initials: HM
authors.lastname: Brink
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Colen
authors.forename: Jan S A G
authors.initials: JS
authors.lastname: Schouten
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D003008:Cloprostenol / Q000031:analogs & derivatives; D004338:Drug Combinations; D016903:Drug Monitoring / Q000295:instrumentation*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D010349:Patient Compliance / Q000706:statistics & numerical data*; D010353:Patient Education as Topic; D011795:Surveys and Questionnaires; D013999:Timolol; D014065:Tonometry, Ocular; D000069557:Travoprost
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D003008:Cloprostenol; D013999:Timolol; D000069557:Travoprost